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Purpose: To investigate the inﬂuence of glycosylated hemoglobin (HbA1c) on treatment outcomes in pa-
tients with diabetic macular edema (DME) receiving intravitreal ranibizumab.
Design: Post hoc analysis of 2 identical phase III clinical trials assessing the efﬁcacy and safety of intravitreal
ranibizumab in DME over 36 months (RIDE: NCT00473382/RISE: NCT00473330).
Participants: A total of 483 adults with vision loss from DME treated with ranibizumab were included in this
analysis from RIDE/RISE. Participants received monthly intravitreal ranibizumab (0.3 or 0.5 mg).
Main Outcome Measures: Differences in visual and anatomic outcomes, and diabetic retinopathy (DR)
severity score, between subgroups of patients with baseline HbA1c 7% versus HbA1c >7% at 36 months.
Results: Therewere 195 patients in RIDE/RISEwhowere treatedwith ranibizumabwith a baselineHbA1c7%
and 288 patients with a baseline HbA1c>7% included in this analysis. The mean improvement in visual acuity (VA)
at 36 months was þ13 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in patients with baseline
HbA1c 7% compared with þ11 ETDRS letters in the patients with a baseline HbA1c >7% (P ¼ 0.17). After
adjustment for baseline central foveal thickness (CFT) and duration of diabetes, the mean CFT reduction was268
mm in patients with a baseline HbA1c 7% and 269 mm in patients with a baseline HbA1c >7% (P ¼ 0.98; 95%
conﬁdence interval, 22.93 to 23.54). The proportion of patients with a 2-step improvement in DR severity score
was 38% in patients with baseline HbA1c 7% compared with 41% in the patients with a baseline HbA1c >7%
(P ¼ 0.53). There was no correlation of baseline HbA1c with any visual or anatomic parameter.
Conclusions: The improvement in VA, anatomic reduction of macular edema, and improvement in DR severity
score with ranibizumab treatment seem to be independent of baseline HbA1c. Ophthalmology 2015;122:1573-
1579 ª 2015 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material is available at www.aaojournal.org.On the basis of a recent multinational meta-analysis of the
burden of diabetic eye disease, the global prevalence of
diabetic macular edema (DME) is estimated to be 7.5%,
affecting approximately 21 million individuals worldwide.1
Vascular endothelial growth factor (VEGF) has been
implicated as an integral target in the complex
pathophysiology of DME.2 Ranibizumab (Lucentis;
Genentech, Inc., South San Francisco, CA) is a monoclonal
antibody fragment speciﬁcally designed for intraocular use
that binds and inhibits all isoforms of the VEGF
molecule.3 On the basis of 2 identical, prospective,
randomized, phase III clinical trials (RIDE/RISE),
intravitreal ranibizumab was approved by the US Food and
Drug Administration for the treatment of DME.4 Patients
undergoing monthly treatment with intravitreal ranibizumab
demonstrated statistically signiﬁcant visual acuity (VA) 2015 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.gains with anatomic improvement compared with sham-
treated patients over 36 months.4,5 In RIDE/RISE, treat-
ment with ranibizumab also signiﬁcantly improved diabetic
retinopathy (DR) severity scores from baseline compared
with sham treatment at 36 months.6
Multiple large epidemiologic studies have shown that
elevated glycosylated hemoglobin (HbA1c) confers an
increased risk of developing DME.1,7e9 However, once a
patient develops DME and requires treatment, it is un-
known whether the patient’s underlying glycemic status
may inﬂuence his or her responses to treatment. In fact,
there is a paucity of data in the literature examining the
inﬂuence of HbA1c on the response to treatment of DME.
The few prior studies on this subject have yielded varying
inconclusive results and are limited by their differing
methodologies.10e141573http://dx.doi.org/10.1016/j.ophtha.2015.04.029
ISSN 0161-6420/15
Ophthalmology Volume 122, Number 8, August 2015The purpose of this analysis is to investigate both the
inﬂuence of baseline HbA1c and the change in HbA1c on
treatment outcomes in a large cohort of patients with DME
treated with ranibizumab in the RIDE/RISE study popu-
lation. The central hypothesis is that patients with DME
and lower baseline HbA1c or improved HbA1c over the
course of the study may have better visual and anatomic
outcomes and improved DR severity scores when treated
with ranibizumab compared with patients with higher
baseline HbA1c or worsening HbA1c over the course of
the study.Methods
Summary of Literature Search
To identify any prior study in the literature regarding the inﬂuence
of HbA1c on treatment outcomes in DME, we performed a broad
literature search in PubMed from the 1950s to the present using a
combination of the terms “anti-VEGF,” “bevacizumab,” “clinically
signiﬁcant macular edema,” “diabetic macular edema,” “diabetic
retinopathy,” “focal laser,” “glycosylated hemoglobin,” “grid
laser,” “HbA1c,” “optical coherence tomography,” “ranibizumab,”
and “vascular endothelial growth factor.” The references of rele-
vant articles were also reviewed to identify additional studies on
the subject matter.RIDE/RISE Trials and Glycosylated Hemoglobin
Measurement
RIDE (registered on clinicaltrials.gov as NCT00473382; accessed
at http://clinicaltrials.gov/show/NCT00473382) and RISE (regis-
tered on clinicaltrials.gov as NCT00473330; accessed at http://
clinicaltrials.gov/show/NCT00473330) are methodologically
identical, phase III, randomized, multicenter, double-masked, 36-
month trials that were sham injectionecontrolled for the ﬁrst 24
months.4 Adults with decreased vision due to center-involved
DME and presence of macular edema documented on time-
domain optical coherence tomography (OCT) were eligible to
enroll. Although spectral-domain OCT is the current imaging
standard at the time of writing this article, patients in RIDE and
RISE were recruited between 2007 and 2009, during which period
time-domain OCT was the standard. Both trials were designed and
conducted in accordance with the principles of the Declaration of
Helsinki and in compliance with the Health Insurance Portability
and Accountability Act. The studies were approved by institutional
review boards, ethics committees, or as applicable. All patients
provided written informed consent before enrolling as participants.
Details of the study methods and key VA and safety ﬁndings
have been reported.4 Brieﬂy, 1 eye per patient was randomized to
monthly treatment with 0.3 mg ranibizumab, 0.5 mg ranibizumab,
or sham injection for the ﬁrst 24 months. Patients who were
originally randomized to ranibizumab continued with monthly
therapy at their assigned dosage through 36 months. Patients
initially randomized to sham were switched to 0.5 mg ranibizumab
monthly starting at month 25. The HbA1c values were drawn at
baseline and 6, 12, 18, 24, and 36 months. The best-corrected VA
(BCVA) of Early Treatment Diabetic Retinopathy Study (ETDRS)
letter score, anatomic outcome of central foveal thickness (CFT) on
time-domain OCT, and DR regression evaluated by the standard-
ized ETDRS severity scale (using fundus photographs) were the
same as previously described.4,61574Inclusion and Exclusion Criteria for Post Hoc
Analysis
Because the baseline distributions of visual, anatomic, and DR
outcomes were similar across both RIDE and RISE trials, data were
pooled for these analyses. All patients in both the RIDE and RISE
trials treated with 0.3 and 0.5 mg ranibizumab were pooled. For all
analyses, visual, anatomic, and DR severity score outcomes are
reported through 36 months for patients who were initially ran-
domized to ranibizumab. Patients in the sham-treated group were
excluded.
Baseline Glycosylated Hemoglobin Analysis
To investigate the inﬂuence of baseline HbA1c on treatment
outcomes, patients were separated into 2 subgroups on the basis
of baseline HbA1c 7% or >7%. This criterion was chosen on
the basis of the 2014 American Diabetes Association position
statement on the generally accepted threshold of diabetic con-
trol.15 In addition, an identical analysis was performed by
separating patients into 4 subgroups based on baseline HbA1c
quartiles (group 1 had baseline HbA1c 6.6%, group 2 had
baseline HbA1c >6.6% and 7.4%, group 3 had baseline
HbA1c >7.4% and 8.5%, and group 4 had baseline
HbA1c >8.5%). The quartiles’ values were selected on the
basis of baseline HbA1c distribution among ranibizumab-
treated patients.Change in Glycosylated Hemoglobin Analysis
To investigate the inﬂuence of the change in HbA1c on treatment
outcomes, patients were separated into 3 subgroups on the basis
of a 0.5% absolute change in HbA1c from baseline to month
36. Group 1 represented “improved” patients whose baseline
HbA1c decreased by >0.5% at month 36. Group 2 represented
“stable” patients whose baseline HbA1c remained within 0.5% at
month 36. Group 3 represented “worsened” patients whose
baseline HbA1c increased by >0.5% at month 36. This criterion
was chosen on the basis of the clinically accepted threshold by
which physicians managing diabetes may expect a clinically
meaningful response in improvement or worsening in glycemic
status.16Statistical Analysis
Missing data were imputed using the last-observation-carried-
forward method on BCVA, CFT, and ETDRS DR severity
scale end points. Analysis of variance or t test was used to
compare the mean change from baseline in BCVA and CFT at
month 36 between HbA1c subgroups. Additional sensitivity an-
alyses were performed for mean change from baseline in CFT
using the covariate-adjusted analysis of covariance model with
baseline CFT value and duration of diabetes as the covariates.
The proportions of patients gaining 15 letters from baseline,
achieving 20/40 Snellen equivalent BCVA, reaching a CFT
250 mm, and attaining 2-step improvement in DR severity
score at month 36 between the subgroups were compared using
Pearson chi-square tests. The KruskaleWallis test or Wilcoxon
rank-sum test was used to examine the median difference in DR
severity score between HbA1c subgroups. In addition, the cor-
relation between baseline HbA1c and visual, anatomic, and DR
severity score was assessed using the Spearman correlation
coefﬁcient.
Table 1. Inﬂuence of Baseline Glycosylated Hemoglobin on Outcomes: Baseline Characteristics and Summary of Results
Characteristic or Outcome Baseline HbA1c £7% (n [ 195) Baseline HbA1c >7% (n [ 288) P Value
Baseline characteristics
HbA1c, % 6.4 (0.4) 8.5 (1.2) e
Age, yrs 63 (9.8) 61 (10.2) e
Male sex, n (%) 123 (63) 156 (54) e
Duration of diabetes, yrs 14 (9.9) 17 (9.1) <0.01
BCVA, ETDRS letters 56 (12.5) 57 (11.4) 0.37
approximate Snellen equivalent 20/80 20/80
CFT, mm 494 (187.2) 456 (140.1) 0.02
Median DR severity scorey 47z 47z 0.90
Vision outcomes at month 36
Change in BCVA from baseline, ETDRS letters þ13 (13.1) þ11 (14.5) 0.17
BCVA, ETDRS letters 69 (14.4) 68 (14.8) 0.57
approximate Snellen equivalent 20/40 20/50
Patients gaining 15 letters from baseline, n (%) 92 (47) 117 (41) 0.15
Patients with Snellen 20/40, n (%) 116 (59) 172 (60) 0.96
Anatomic outcomes at month 36
Change in CFT from baseline, mm 292 (204.8) 253 (178.0) 0.03
Change in CFT from baseline, mm, adjusted LS mean (SE)* 268 (9.1) 269 (7.4) 0.98
CFT, mm 203 (129.9) 204 (115.7) 0.93
Patients with CFT 250 mm, n (%) 157 (81) 236 (82) 0.69
DR severity score at month 36y
Median DR severity score 35z 35z 0.64
Patients with 2-step improvement, n (%) 69 (38) 110 (41) 0.53
Data are mean (standard deviation) unless otherwise indicated.
BCVA ¼ best-corrected visual acuity; CFT ¼ central foveal thickness; DR ¼ diabetic retinopathy; ETDRS ¼ Early Treatment Diabetic Retinopathy Study;
HbA1c ¼ glycosylated hemoglobin; LS ¼ least squares; SE ¼ standard error.
*Analysis of covariance model with baseline CFT and duration of diabetes as covariates was used to estimate the adjusted LS mean.
yETDRS DR severity was available for analysis in 451 patients treated with ranibizumab included.
zSeverity level: 47 ¼ moderate to severe nonproliferative DR; 35 ¼ mild nonproliferative DR.
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Figure 1. Mean change in best-corrected visual acuity (BCVA) over 36
months in ranibizumab-treated patients with baseline glycosylated hemo-
globin (HbA1c) 7% compared with HbA1c >7%. Error bars represent
1 standard error.
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Baseline Glycosylated Hemoglobin Analysis
(Baseline Characteristics)
A total of 759 patients with DME were enrolled and randomized to
ranibizumab or sham treatment in RIDE/RISE. This analysis fo-
cuses on the 483 patients who were treated with ranibizumab with
baseline HbA1c data available (baseline HbA1c 7%: n ¼ 195;
baseline HbA1c >7%: n ¼ 288). Baseline demographics are
summarized in Table 1. Baseline BCVA and DR severity of the
study eye were not signiﬁcantly different between HbA1c
subgroups (P ¼ 0.37 and 0.90, respectively). Baseline CFT was
signiﬁcantly thicker in the subgroup of patients with baseline
HbA1c 7% compared with patients with baseline HbA1c >7%
(P ¼ 0.02).
Baseline Glycosylated Hemoglobin and Visual
Outcomes
Visual, anatomic, and DR severity score results are summarized in
Table 1. At month 36, patients with baseline HbA1c 7% gained a
mean of þ13 letters from baseline (standard deviation [SD], 13.1)
compared with patients with baseline HbA1c >7%, who gained a
mean of þ11 letters from baseline (SD, 14.5) (Fig 1). The mean
improvement between the HbA1c subgroups was not
signiﬁcantly different (P ¼ 0.17; 95% conﬁdence interval
[CI], 0.78 to 4.31). From baseline to month 36, 47% ofpatients with baseline HbA1c 7% gained 15 letters compared
with 41% of patients with baseline HbA1c >7% (P ¼ 0.15). At
month 36, 59% of patients with baseline HbA1c 7% achieved
BCVA of 20/40 compared with 60% of patients with baseline
HbA1c >7% (P ¼ 0.96).1575
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Figure 2. Mean change in central foveal thickness (CFT) over 36 months
in ranibizumab-treated patients with baseline glycosylated hemoglobin
(HbA1c) 7% compared with HbA1c >7%. Error bars represent 1
standard error.
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Figure 3. Percentage of patients with 2-step improvement in diabetic
retinopathy severity score at month 36 among ranibizumab-treated patients
with baseline glycosylated hemoglobin (HbA1c) 7% compared with
HbA1c >7%. Error bars represent 1 standard error.
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Outcomes
At baseline, there was a signiﬁcant difference in CFT between the
subgroups (baseline HbA1c 7%: 494 mm vs. baseline HbA1c
>7%: 456 mm; P ¼ 0.02). At month 36, the mean CFT reduction
from baseline was 292 mm (SD, 204.8 mm) and 253 mm (SD,
178.0 mm) in patients with baseline HbA1c 7% and >7%,
respectively (P ¼ 0.03; 95% CI, 74.44 to 3.53) (Fig 2).
However, after adjustment for baseline CFT and duration of
diabetes, the mean CFT reduction was 268 mm in patients with
a baseline HbA1c 7% and 269 mm in patients with a baseline
HbA1c >7% (P ¼ 0.98; 95% CI, 22.93 to 23.54). The
percentage of patients with a CFT 250 mm at month 36 was
similar between baseline HbA1c subgroups (baseline HbA1c
7%: 81%; baseline HbA1c >7%: 82%; P ¼ 0.69).
Baseline Glycosylated Hemoglobin and Early
Treatment Diabetic Retinopathy Study Diabetic
Retinopathy Severity Outcomes
At baseline, the median ETDRS DR severity level was 47 in both
HbA1c subgroups, which corresponds to moderate to severe non-
proliferative DR (moderate severe nonproliferative DR).17 The
median ETDRS DR severity level at month 36 was 35 in both
HbA1c subgroups, which corresponds to mild nonproliferative
DR. The proportion of patients with a 2-step improvement in
DR severity score was 38% among patients with baseline HbA1c
7% compared with 41% among patients with a baseline HbA1c
>7% (P ¼ 0.53) (Fig 3).
Baseline Glycosylated Hemoglobin Analysis Using
Quartile Stratiﬁcation
An identical analysis to the one just described was carried out,
separating patients into 4 subgroups using quartiles of baseline
HbA1c. Group 1 had baseline HbA1c 6.6% (n ¼ 116), group 2
had baseline HbA1c >6.6% and 7.4% (n ¼ 140), group 3 had
baseline HbA1c >7.4% and 8.5% (n ¼ 113), and group 4 had1576baseline HbA1c >8.5% (n ¼ 114). There was no difference among
any subgroups regarding VA, anatomic, or DR severity score
outcomes (Table 2, available at www.aaojournal.org).
Correlation of Baseline Glycosylated Hemoglobin to
Visual, Anatomic, and Diabetic Retinopathy
Severity Score
In the pooled analysis of ranibizumab-treated patients, there was no
correlation between baseline HbA1c and improvement in BCVA,
36-month BCVA, change in CFT, 36-month CFT, improvement in
DR severity score, or 36-month DR severity score.
Change in Glycosylated Hemoglobin Analysis
(Baseline Characteristics)
Of the 483 patients treated with ranibizumab, 371 had HbA1c data
available at month 36 for analysis. Group 1 represented
“improved” patients whose baseline HbA1c decreased by >0.5%
at month 36 (n ¼ 93), group 2 represented “stable” patients whose
baseline HbA1c remained within 0.5% at month 36 (n ¼ 139), and
group 3 represented “worsened” patients whose baseline HbA1c
increased by >0.5% at month 36 (n ¼ 139). Baseline de-
mographics are summarized in Table 3. Baseline BCVA, CFT, and
DR severity level of the study eye were not signiﬁcantly different
between HbA1c subgroups (P ¼ 0.30, 0.34, and 0.17,
respectively).
Change in Glycosylated Hemoglobin and Visual
Outcomes
At month 36, patients with “improved” HbA1c gained a mean
of þ12 letters from baseline (SD, 15.9) compared with patients
with “stable” HbA1c, who gained a mean of þ13 letters from
baseline (SD, 13.1), and compared with patients with “worsened”
HbA1c, who gained a mean of þ15 letters from baseline (SD, 13.4;
P ¼ 0.23). There was no statistically signiﬁcant difference in the
other VA outcome parameters among the 3 subgroups (Table 3).
Change in Glycosylated Hemoglobin and Anatomic
Outcomes
At month 36, patients with improved, stable, or worsened HbA1c
had similar CFT (209, 193, and 176 mm, respectively; P ¼ 0.08)
Table 3. Inﬂuence of Change of Glycosylated Hemoglobin on Outcomes: Baseline Characteristics and Summary of Results
Characteristic or Outcome
HbA1c Improved*
(n [ 93)
HbA1c Stable*
(n [ 139)
HbA1c Worsened*
(n [ 139) P Value
Baseline characteristics
HbA1c, % 8.5 (1.5) 7.3 (1.2) 7.4 (1.2) e
Age, yrs 63 (8.6) 63 (10.4) 61 (10.0) e
Male, n (%) 51 (55) 92 (66) 76 (55) e
Duration of diabetes, yrs 16 (11.1) 16 (9.8) 15 (8.7) 0.41
BCVA, ETDRS letters 55 (11.9) 58 (10.4) 57 (13.2) 0.30
approximate Snellen equivalent 20/80 20/80 20/80
CFT, mm 457 (144.6) 489 (175.7) 480 (161.8) 0.34
Median DR severity scorey 47z 47z 47z 0.17
Vision outcomes at month 36
Change in BCVA from baseline, ETDRS letters þ12 (15.9) þ13 (13.1) þ15 (13.4) 0.23
BCVA, ETDRS letters 67 (14.9) 70 (13.3) 71 (15.1) 0.07
approximate Snellen equivalent 20/50 20/40 20/40
Patients gaining 15 letters from baseline, n (%) 41 (44) 66 (47) 70 (50) 0.64
Patients with Snellen 20/40, n (%) 51 (55) 90 (65) 96 (69) 0.08
Anatomic outcomes at month 36
Change in CFT from baseline, mm 248 (176.8) 295 (200.1) 304 (178.3) 0.06
Change in CFT from baseline, mm, adjusted LS mean (SE)x 267 (11.8) 285 (9.7) 301 (9.6) 0.08
CFT, mm 209 (126.4) 193 (111.0) 176 (99.4) 0.08
Patients with CFT 250 mm, n (%) 75 (81) 115 (83) 127 (91) 0.04
DR severity score at month 36y
Median DR severity score 35z 35z 35z 0.86
Patients with 2-step improvement, n (%) 33 (38) 58 (44) 64 (50) 0.21
Data are mean (standard deviation) unless otherwise indicated.
BCVA ¼ best-corrected visual acuity; CFT ¼ central foveal thickness; DR ¼ diabetic retinopathy; ETDRS ¼ Early Treatment Diabetic Retinopathy Study;
HbA1c ¼ glycosylated hemoglobin; LS ¼ least squares; SE ¼ standard error.
*Improved deﬁned as >0.5% absolute value decrease in HbA1c at month 36 from baseline; Stable deﬁned as an increase or decrease of 0.5%; worsened
deﬁned as >0.5% absolute value increase in HbA1c at month 36 from baseline.
yETDRS DR severity was available for analysis in 348 patients treated with ranibizumab included.
zSeverity level: 47 ¼ moderate to severe nonproliferative DR; 35 ¼ mild nonproliferative DR.
xAnalysis of covariance model with baseline CFT and duration of diabetes as covariates was used to estimate the adjusted LS mean.
Bansal et al  Inﬂuence of HbA1c on Efﬁcacy of Ranibizumab for DME(Table 3). The mean reduction in CFT from baseline at month 36
was 248 mm (SD, 176.8 mm), 295 mm (SD, 200.1 mm),
and 304 mm (SD, 178.3 mm) in the improved, stable, and
worsened HbA1c groups, respectively (P ¼ 0.06).
Change in Glycosylated Hemoglobin and Early
Treatment Diabetic Retinopathy Study Diabetic
Retinopathy Severity Outcomes
At month 36, there was no statistically signiﬁcant difference in the
median DR severity score or percentage of patients with a 2-step
improvement in DR severity score among the subgroups of patients
with improved, stable, or worsened HbA1c (Table 3).
Discussion
Prior studies investigating the relationship of HbA1c on the
response to treatment of DME have varied greatly in their
methodology, ranging from disease state studied (treatment-
naive DME vs. refractory DME), intervention (ranibizumab
vs. bevacizumab vs. laser), outcome measures (ﬁnal VA vs.
change in VA), and correlation of HbA1c to various
outcome parameters (baseline VA or CFT, ﬁnal VA or CFT,
or change in VA or CFT). These differences coupled with
smaller sample sizes and retrospective design limit theclinician’s ability to draw meaningful conclusions regarding
this fundamental and important clinical question: Does
HbA1c inﬂuence the outcomes in patients treated for DME?
Before the anti-VEGF era, Do et al10 reported that
patients with “persistent” DME had higher HbA1c
concentrations compared with patients with resolved
DME, suggesting that tighter glycemic control may
prevent persistent DME. However, the study was limited
by its selection bias given its small retrospective design
and lack of VA outcomes reported. In a small prospective
study of 30 patients, Schmid et al13 found that there was
no correlation between the baseline HbA1c and the
reduction of CFT after focal laser for DME.
In the anti-VEGF era, we identiﬁed 3 prior studies that
compared the differences in treatment outcomes between
subgroups of patients on the basis of baseline HbA1c con-
centrations (7% or >7%). In a small prospective analysis
of 38 patients treated with a single intravitreal injection of
bevacizumab for refractory clinically signiﬁcant DME,
Warid Al-Laftah et al14 demonstrated that a greater
proportion of patients with HbA1c <7% gained 2 lines of
VA compared with those with HbA1c >7%, suggesting
that poorer glycemic control may lead to worse visual
outcomes. By contrast, in a prospective study of 52
patients, Macky and Mahgoub11 reported that there was1577
Ophthalmology Volume 122, Number 8, August 2015no difference in the 6-month VA or CFT between patients
with baseline HbA1c <7% or 7% treated with 3 injections
of bevacizumab plus laser for treatment-naive DME.
More recently, in a retrospective analysis of 124 patients
treated with approximately 6 injections of bevacizumab for
treatment-naive DME over 12 months, Matsuda et al12
demonstrated that patients with an initial HbA1c 7% had
better 12-month VA (20/43) compared with patients with
an initial HbA1c >7% (20/62). However, there was no
signiﬁcant difference in the ﬁnal CFT between the 2 groups;
that is, both groups had signiﬁcant reductions in CFT after
treatment regardless of their glycemic control. The authors
concluded that “patients with more optimal HbA1c achieve
better ﬁnal BCVA after one year of bevacizumab treat-
ment.” However, it is worthwhile to note that patients in this
study with HbA1c >7% had worse baseline vision
compared with patients with HbA1c <7%, which alone may
confound the results.
In the present study, we demonstrate that patients treated
with monthly intravitreal ranibizumab have improvement in
VA, reduction in CFT, and improvement in DR severity
score independent of their baseline HbA1c or change in
HbA1c. We found no signiﬁcant differences in the 36-
month vision, change in vision, or 36-month CFT between
patients with baseline HbA1c 7% and >7%, or between
patients stratiﬁed by quartiles of baseline HbA1c. Our re-
sults are similar to those of Ozturk et al,18 who found no
relationship between the baseline HbA1c and
improvement in VA after a single intravitreal injection of
ranibizumab. Although there was a statistically signiﬁcant
difference in the change in CFT from baseline at 36
months between the 2 groups, this could be accounted for
by the fact that the baseline CFT was signiﬁcantly thicker
in the group with baseline HbA1c 7%. Matsuda et al12
and Macky and Mahgoub11 reported similar ﬁndings. It is
unclear why patients with baseline HbA1c 7% had
thicker CFT at baseline compared with those with HbA1c
>7%, but it is a ﬁnding that warrants further
investigation. After adjustment for baseline CFT values
and duration of diabetes, there was no statistically
signiﬁcant difference between the 2 groups in change in
CFT from baseline to 36 months. Furthermore, the
proportion of patients with CFT 250 mm at month 36
was high (>80%) and similar between both groups.
In addition to analyzing the effect of baseline HbA1c, we
also found no difference in the 36-month vision, change in
vision, proportion of patients gaining 15 letters, proportion
of patients with 20/40 BCVA, 36-month CFT, or DR
severity score outcomes among the 3 subgroups of patients
with improved, stable, or worsened HbA1c throughout the
study. The question of how best to evaluate a clinically
meaningful change in HbA1c is a challenging one, and one
that currently has no consensus in the diabetic literature.
After a thorough review of the literature, we chose a plau-
sible threshold of 0.5% which is the criterion many phy-
sicians managing diabetes use to evaluate response to
systemic treatments.16 We acknowledge that this cutoff may
not represent an equally meaningful change based on
differing levels of HbA1c. For instance, a change from
HbA1c of 10.1% to 9.6% may be more clinically relevant1578than a change from HbA1c of 6.8% to 6.3%. Further
work is needed to better deﬁne clinically meaningful
change in HbA1c when examining clinical studies.
There could be several reasons for the differences in our
results and those of prior studies. First, DME is undoubtedly
a complex condition that occurs after patients have diabetes
for an extended period of time, the improvement or wors-
ening of which likely depends on a multitude of ﬂuctuating
systemic and local factors, such as blood pressure, choles-
terol, obesity, and genetics, and not purely on HbA1c or
VEGF inhibition alone. Second, direct comparison of our
results taken from a standardized clinical trial with those of a
small retrospective study is difﬁcult. The key strengths of
our analysis include data derived from a large, prospectively
obtained sample size treated with regular ranibizumab and
close follow-up in a standardized fashion. Of note, we are
able to provide long-term follow-up (36 months), which
allowed comparisons at various time points. Glycemic
control undoubtedly ﬂuctuates from month to month and
year to year; therefore, capturing long-term data over 36
months is critical to assessing any effect of glycemic control
on treatment outcomes. Notwithstanding, we acknowledge
that RIDE/RISE patients had diabetes for more than 15
years on average, and a 3-year time period is a relatively
small window in the total life of a diabetic patient.Study Limitations
There are certain limitations to this study. As with any post
hoc analysis, we must exercise caution in interpreting our
results as causal and not purely coincidental. Patients in the
RIDE/RISE trials were closely monitored and treated
monthly regardless of VA or OCT ﬁndings, a practice that is
infrequently encountered in clinical practice outside of a
formal clinical trial. As such, it is possible that the group
with baseline HbA1c 7% could have achieved excellent
VA with less frequent dosing. Conversely, it is possible that
patients with baseline HbA1c >7% required frequent
monthly treatment to maintain their excellent visual and
anatomic results. At some point, there may be a threshold
beyond which VA fails to improve despite additional
treatment. In addition, patients in the RIDE/RISE trials may
have had better controlled and stable HbA1c than what is
typically seen in clinical practice because of the controlled
clinical trial setting. To fully explore our hypothesis and
isolate HbA1c as an independent risk factor, patients with
DME who have similar baseline vision and CFT would need
to be randomized according to HbA1c and prospectively
studied according to a certain treatment protocol. A study of
this nature would be technically and ﬁnancially unfeasible.
Because of our large sample size, relatively balanced
subgroups at the outset, and same treatment protocol for
each subgroup, we are conﬁdent that our results may guide
clinicians in answering a common clinical question: What is
the role of glycemic control in the treatment of DME?
Although HbA1c remains an important marker for systemic
control of diabetes mellitus, our results suggest that patients
with DME treated with regular intravitreal ranibizumab on
average achieve improvement in visual, anatomic, and DR
Bansal et al  Inﬂuence of HbA1c on Efﬁcacy of Ranibizumab for DMEoutcomes independent of their baseline HbA1c or change in
HbA1c.
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